Fulvestrant

Generic Name: Fulvestrant

Brand Names: Faslodex, Fulvestrant Mylan

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₇F_₅O_₃S

CAS Number: 129453-61-8

Unique Ingredient Identifier: 22X328QOC4

Background: Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer

Indication: For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions: Advanced Breast Cancer, Advanced or Metastatic Breast Cancer

Associated Therapies: -

Clinical Trials

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Debio 1347

First Posted Date: 2017-11-17

Last Posted Date: 2022-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT03344536

Locations: 🇺🇸
Memorioal Sloan Kettering Cancer Center, New York, New York, United States

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

Phase 2

Terminated

Conditions: Breast Cancer Metastatic

Interventions: Drug: Capecitabine
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2017-10-26

Last Posted Date: 2024-03-08

Lead Sponsor: Theodoros Foukakis

Target Recruit Count: 42

Registration Number: NCT03322215

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Uppsala University Hospital, Uppsala, Sweden
🇬🇧
NHS Grampian, Aberdeen, United Kingdom

and more 6 locations

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1

Completed

Conditions: Breast Cancer
Prostate Cancer
Advanced Solid Tumors

Interventions: Drug: AZD5363
Drug: Enzalutamide
Drug: Fulvestrant

First Posted Date: 2017-10-16

Last Posted Date: 2023-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT03310541

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1

Terminated

Conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
Metastatic Epithelial Ovarian Cancer
HER2-Negative Breast Cancer

Interventions: Drug: Ribociclib
Drug: PDR001
Drug: Fulvestrant

First Posted Date: 2017-09-27

Last Posted Date: 2022-03-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT03294694

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Neratinib
Drug: Fulvestrant

First Posted Date: 2017-09-20

Last Posted Date: 2024-02-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT03289039

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 3 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Drug: Ipatasertib
Drug: Entinostat
Drug: Fulvestrant
Drug: Bevacizumab
Drug: Exemestane
Drug: Abemaciclib
Drug: Tamoxifen

First Posted Date: 2017-09-12

Last Posted Date: 2024-10-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 138

Registration Number: NCT03280563

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 24 locations

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Seribantumab
Drug: Fulvestrant
Drug: Placebo

First Posted Date: 2017-08-08

Last Posted Date: 2020-09-02

Lead Sponsor: Elevation Oncology

Target Recruit Count: 22

Registration Number: NCT03241810

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
University of Mississippi, Jackson, Mississippi, United States
🇺🇸
University of Utah Health Care - Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 56 locations

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Erdafitinib
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2017-08-03

Last Posted Date: 2024-11-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 35

Registration Number: NCT03238196

Locations: 🇺🇸
Baptist Memorial Hospital MEMPHIS, Memphis, Tennessee, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 3 locations